Antara Capital LP Durect Corp Transaction History

Antara Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $5.9 $131,526 - $1.8 Million	305,876 Added 6.56%	4,970,713 $2.87 Million
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.64 $32,300 - $54,400	85,000 Added 1.86%	4,664,837 $2.23 Million
Q1 2022 May 16, 2022	BUY	$0.55 - $0.98 $110,000 - $196,000	200,000 Added 4.57%	4,579,837 $3.07 Million
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $1.01 Million - $1.46 Million	1,117,151 Added 34.24%	4,379,837 $4.32 Million
Q3 2021 Nov 15, 2021	BUY	$1.21 - $1.61 $972,962 - $1.29 Million	804,101 Added 32.71%	3,262,686 $4.18 Million
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $800,000 - $1.01 Million	500,000 Added 25.53%	2,458,585 $4.01 Million
Q1 2021 May 17, 2021	BUY	$1.86 - $2.87 $3.64 Million - $5.62 Million	1,958,585 New	1,958,585 $3.88 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $173M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Antara Capital LP, based on Form 13F filings with the SEC.

Stay updated on Antara Capital LP with notifications on news.